SM
ONC

SG3 Management’s BeOne Medicines Ltd ONC Stock Holding History

SG3 Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,000
Closed -$971K – 465
2022
Q2 		$971K Sell
6,000
-9,000
-60% -$1.41M 0.11% 134
2022
Q1 		$2.83M Hold
15,000
– – 0.08% 235
2021
Q4 		$4.06M Buy
+15,000
New +$5.06M 0.08% 214
2021
Q2 		– Sell
-13,500
Closed -$4.7M – 1402
2021
Q1 		$4.7M Hold
13,500
– – 0.12% 190
2020
Q4 		$3.49M Buy
13,500
+8,500
+170% +$2.34M 0.07% 263
2020
Q3 		$1.43M Buy
+5,000
New +$1.18M 0.05% 344

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

SG3 Management's ONC Position: Q1 2022 in Review

SG3 Management sold out of BeOne Medicines Ltd (ONC) in Q1 2022, closing a stake of 2,500 shares — an estimated $531K sold.

SG3 Management first reported a position in ONC in Q3 2021 and held it in 2 quarters. The position peaked at $1.45M in Q3 2021. 238 funds tracked by Wall St. Rank hold ONC as of Q1 2022.

  • SG3 Management reported no remaining BeOne Medicines Ltd position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 2,500 BeOne Medicines Ltd shares in Q1 2022, an estimated $531K.
  • SG3 Management first reported a position in BeOne Medicines Ltd in Q3 2021 and held it in 2 quarters.
  • SG3 Management's BeOne Medicines Ltd position peaked at $1.45M in Q3 2021.
  • 238 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.